Head-to-head evidence
Aflibercept vs MW02
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Aflibercept · Eylea
Marketed by Regeneron Pharmaceuticals and partners
NCT00509795 · Phase 3 · completed
The trial randomly assigned 1,217 participants and used quadruple blinding with ranibizumab as an active comparator. Its hard clinical primary endpoint—maintaining vision at week 52—met the prespecified non-inferiority criterion for all three aflibercept regimens, supporting a strong evidence grade.
Next expected readout: December 2026 · NCT06856577 (registry estimate)
MW02
Developed by Mabwell (Shanghai) Bioscience Co., Ltd.
NCT05297292 · Phase 2/3 · status unknown
This is a randomized, quadruple-blind, active-controlled Phase 2/3 trial with a clinically meaningful primary endpoint (change in visual acuity), but no results have been posted yet, so the treatment effect versus the active comparator is still unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept's landscape · MW02's landscape